Pages that link to "Q34935716"
Jump to navigation
Jump to search
The following pages link to American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy (Q34935716):
Displaying 50 items.
- KRAS mutational analysis for colorectal cancerApplication: Pharmacogenomic (Q21128654) (← links)
- Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer (Q21142734) (← links)
- Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab (Q24600031) (← links)
- Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options (Q26738655) (← links)
- Current targeted therapies in the treatment of advanced colorectal cancer: a review (Q26740067) (← links)
- Pharmacologic resistance in colorectal cancer: a review (Q26769850) (← links)
- Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer (Q26769935) (← links)
- Somatic DNA mutation analysis in targeted therapy of solid tumours (Q26770324) (← links)
- Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine (Q26783472) (← links)
- Precision medicine in colorectal cancer: the molecular profile alters treatment strategies (Q26795558) (← links)
- Personalized treatment for advanced colorectal cancer: KRAS and beyond (Q26822817) (← links)
- K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value (Q26829425) (← links)
- Recent applications of chemosensitivity tests for colorectal cancer treatment (Q26851075) (← links)
- Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer (Q26853171) (← links)
- Molecular alterations and biomarkers in colorectal cancer (Q26862317) (← links)
- Cancer biomarkers (Q26864429) (← links)
- Colorectal Cancer Biomarkers: Where Are We Now? (Q27003134) (← links)
- Novel immunotherapeutic strategies of gastric cancer treatment (Q27011232) (← links)
- Guanylyl cyclase C as a biomarker in colorectal cancer (Q27011759) (← links)
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (Q27015224) (← links)
- Genetic and epigenetic traits as biomarkers in colorectal cancer (Q27016019) (← links)
- Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era (Q27693248) (← links)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis (Q27851573) (← links)
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (Q27851586) (← links)
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. (Q27851616) (← links)
- mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors (Q27851707) (← links)
- Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. (Q27851892) (← links)
- The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis (Q27852988) (← links)
- CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (Q27853338) (← links)
- Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases (Q28067408) (← links)
- Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective (Q28070038) (← links)
- RAS isoforms and mutations in cancer at a glance (Q28070394) (← links)
- Mechanisms of resistance to anti-EGFR therapy in colorectal cancer (Q28074073) (← links)
- RAS and BRAF in metastatic colorectal cancer management (Q28074175) (← links)
- Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status (Q28082816) (← links)
- Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers (Q28087333) (← links)
- ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development (Q28115416) (← links)
- Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival (Q28258483) (← links)
- Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature (Q28468648) (← links)
- PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis (Q28543278) (← links)
- Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer (Q28728593) (← links)
- Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation (Q28730199) (← links)
- Evolving Therapies and FAK Inhibitors for the Treatment of Cancer (Q28972291) (← links)
- Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors (Q30276632) (← links)
- Informing materials: drugs as tools for exploring cancer mechanisms and pathways (Q30402161) (← links)
- Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond (Q30416074) (← links)
- High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing (Q30514084) (← links)
- Clinical analysis and interpretation of cancer genome data (Q30617093) (← links)
- Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer (Q30838052) (← links)
- Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system (Q30870757) (← links)